论文部分内容阅读
2011年10月,美国FDA批准了Waston制药有限公司开发的睾丸酮(testosterone)透皮贴剂Androderm2和4mg/d新制剂,后者较前获准上市的Androderm制剂尺寸小且剂量低20%。Androderm新制剂的推荐起
In October 2011, the FDA approved the testosterone transdermal patch Androderm 2 and the new 4 mg / d formulation developed by Waston Pharmaceuticals, Inc., which were smaller and 20% lower dosage than the previously approved Androderm formulations. Recommended for Androderm’s new formulation